A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: John C. Byrd |
| Publication date | March 10, 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |